Acute Myeloid Leukemia

EMEA grants orphan drug designation to Troxatyl for acute myeloid leukemia

Published in Cancer Weekly, October 25th, 2005

SGX Pharmaceuticals, Inc., (SGX) announced that Troxatyl has been granted orphan drug status for the treatment of acute myeloid leukemia (AML) by the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA).

Troxatyl is currently in a pivotal phase II/III clinical trial for the third-line treatment of AML. The company announced earlier in May that the U.S. Food & Drug Administration had granted Troxatyl orphan drug designation in the U.S. for the treatment of AML.

The EMEA orphan drug designation provides incentives to companies that develop drugs for diseases affecting no more than 50 in 100,000 persons in the European Union...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-10-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry